Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 475 of 2026 entries
View as:

A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)

Phase: N/A Priority: Normal
NCT ID: NCT02641379 Org: User:
Start: 05/31/03 End: 11/30/13 Due: 11/30/14

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05769959 Org: User:
Start: 06/15/23 End: 03/19/24 Due: 03/19/25

A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02711423 Org: User:
Start: 03/31/16 End: 09/28/16 Due: 09/28/17

An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05251948 Org: User:
Start: 03/01/22 End: 12/31/25 Due: 12/31/26

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT02340234 Org: User:
Start: 05/31/15 End: 04/30/16 Due: 04/30/17

A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00576901 Org: User:
Start: 11/30/07 End: 06/30/09 Due: 06/30/10

A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048

Phase: N/A Priority: Normal
NCT ID: NCT01099904 Org: User:
Start: 03/31/10 End: 09/30/10 Due: 09/30/11

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

Phase: N/A Priority: Normal
NCT ID: NCT00408213 Org: User:
Start: 06/30/04 End: 09/30/07 Due: 09/30/08

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00087646 Org: User:
Start: 09/30/03 End: 05/31/08 Due: 05/31/09

A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02701985 Org: User:
Start: 07/05/16 End: 07/10/17 Due: 07/10/18

An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT01634542 Org: User:
Start: 02/28/11 End: 12/31/14 Due: 12/31/15

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT01493336 Org: User:
Start: 05/31/12 End: 10/31/12 Due: 10/31/13

A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels

Phase: N/A Priority: Normal
NCT ID: NCT02726022 Org: User:
Start: 02/28/07 End: 07/31/11 Due: 07/31/12

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03337724 Org: User:
Start: 01/06/18 End: 01/04/23 Due: 01/04/24

A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment

Phase: N/A Priority: Normal
NCT ID: NCT03558490 Org: User:
Start: 06/12/18 End: 04/19/19 Due: 04/19/20

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Phase: N/A Priority: Normal
NCT ID: NCT02409342 Org: User:
Start: 07/20/15 End: 03/08/22 Due: 03/08/23

A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase: N/A Priority: Normal
NCT ID: NCT02707640 Org: User:
Start: 08/31/13 End: 02/28/15 Due: 02/28/16

A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02019277 Org: User:
Start: 12/05/13 End: 11/04/16 Due: 11/04/17

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02639546 Org: User:
Start: 05/20/16 End: 07/21/21 Due: 07/21/22

A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.

Phase: N/A Priority: Normal
NCT ID: NCT00605345 Org: User:
Start: 12/31/07 End: 07/31/09 Due: 07/31/10

An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01575769 Org: User:
Start: 01/19/12 End: 12/03/13 Due: 12/03/14

Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples

Phase: N/A Priority: Normal
NCT ID: NCT02580799 Org: User:
Start: 02/28/14 End: 10/31/14 Due: 10/31/15

A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Phase: N/A Priority: Normal
NCT ID: NCT05199688 Org: User:
Start: 06/30/25 End: 12/14/29 Due: 12/14/30

Bevacizumab in Metastatic Renal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02627144 Org: User:
Start: 01/31/08 End: 09/30/14 Due: 09/30/15

A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive

Phase: N/A Priority: Normal
NCT ID: NCT01086085 Org: User:
Start: 04/30/10 End: 03/31/13 Due: 03/31/14